Invest rubles in iShares NASDAQ Biotechnology
Sberbank urged Russians to invest
to American biotech firms
Ekaterina Makarova, Vademecum
Sberbank Asset Management has offered Russian retail clients shares of an open mutual fund of Sberbank-Biotechnologies funds, the funds of which will be invested in shares of the American exchange-traded fund (ETF) iShares NASDAQ Biotechnology with assets of $8.8 billion under the management of Blackrock Fund Advisors.
According to Vedomosti, NASDAQ Biotechnology includes shares of 146 major biotech and pharmaceutical companies specializing in the development of new medicines. According to the rules of the ETF fund, the share of funds in the new mutual fund should not exceed 25% of assets.
According to Anton Rakhmanov, CEO of Sberbank Asset Management, the new fund is currently the only opportunity for retail investments in a diversified portfolio of biotech companies. At the same time, the specialist recommends investing in the fund for a long time. According to Rakhmanov, the biotech sector is located beyond the boundary of economic cycles, so it will give a good increase in assets in the near future. The minimum initial investment in the fund is 15 thousand rubles, repeated – 1.5 thousand rubles.
The success of biotech concerns is due to the high demand for innovative developments, market experts are sure. At the same time, the main hopes are pinned on effective cancer drugs and medications for the treatment of other serious diseases.
The biotech industry as a direction for long-term investments attracts many analysts, in particular BCS, Alfa-Capital, Arbat Capital. According to the publication, this sector has become the fastest growing in the US economy over the past five years (an increase of 277.6%). The annual growth rate of NASDAQ Biotechnology has almost reached 19%, which is more than similar indicators of another stock index – the S&P 500, analysts say.
In the near future, according to experts, the shares of many biotech companies are expected to grow. For example, the growth potential of Gilead Sciences is estimated at 43%, AbbVie at 44%, Curis Inc and Keryx Biopharma at 78%.
Analysts also emphasize that investments in the new fund, similar to contributions to other mutual funds that track the dynamics of foreign exchange assets on the world market, can serve as insurance against the devaluation of the ruble and a form of currency diversification.
Portal "Eternal youth" http://vechnayamolodost.ru02.06.2015